218 related articles for article (PubMed ID: 24584817)
1. Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1.
Krishnadas DK; Bao L; Bai F; Chencheri SC; Lucas K
Tumour Biol; 2014 Jun; 35(6):5753-62. PubMed ID: 24584817
[TBL] [Abstract][Full Text] [Related]
2. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.
Bao L; Dunham K; Lucas K
Cancer Immunol Immunother; 2011 Sep; 60(9):1299-307. PubMed ID: 21626030
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma.
Krishnadas DK; Shusterman S; Bai F; Diller L; Sullivan JE; Cheerva AC; George RE; Lucas KG
Cancer Immunol Immunother; 2015 Oct; 64(10):1251-60. PubMed ID: 26105625
[TBL] [Abstract][Full Text] [Related]
4. Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules.
Adair SJ; Hogan KT
Cancer Immunol Immunother; 2009 Apr; 58(4):589-601. PubMed ID: 18791715
[TBL] [Abstract][Full Text] [Related]
5. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
[TBL] [Abstract][Full Text] [Related]
6. Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma.
Li B; Zhu X; Sun L; Yuan L; Zhang J; Li H; Ye Z
Oncotarget; 2014 Nov; 5(21):10791-802. PubMed ID: 25301731
[TBL] [Abstract][Full Text] [Related]
7. Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.
Krishnadas DK; Wang Y; Sundaram K; Bai F; Lucas KG
Tumour Biol; 2017 Jul; 39(7):1010428317701309. PubMed ID: 28677424
[TBL] [Abstract][Full Text] [Related]
8. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
[TBL] [Abstract][Full Text] [Related]
9. Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing.
Klar AS; Gopinadh J; Kleber S; Wadle A; Renner C
PLoS One; 2015; 10(10):e0139221. PubMed ID: 26447882
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts.
Srivastava P; Paluch BE; Matsuzaki J; James SR; Collamat-Lai G; Taverna P; Karpf AR; Griffiths EA
Epigenetics; 2015; 10(3):237-46. PubMed ID: 25793777
[TBL] [Abstract][Full Text] [Related]
11. A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.
Gunda V; Frederick DT; Bernasconi MJ; Wargo JA; Parangi S
Thyroid; 2014 Aug; 24(8):1241-50. PubMed ID: 24811699
[TBL] [Abstract][Full Text] [Related]
12. Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer.
Gunda V; Cogdill AP; Bernasconi MJ; Wargo JA; Parangi S
Surgery; 2013 Dec; 154(6):1456-62; discussion 1462. PubMed ID: 24238058
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer.
Chou J; Voong LN; Mortales CL; Towlerton AM; Pollack SM; Chen X; Yee C; Robbins PF; Warren EH
J Immunother; 2012; 35(2):131-41. PubMed ID: 22306901
[TBL] [Abstract][Full Text] [Related]
14. The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma.
Natsume A; Wakabayashi T; Tsujimura K; Shimato S; Ito M; Kuzushima K; Kondo Y; Sekido Y; Kawatsura H; Narita Y; Yoshida J
Int J Cancer; 2008 Jun; 122(11):2542-53. PubMed ID: 18240144
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.
Schrump DS; Fischette MR; Nguyen DM; Zhao M; Li X; Kunst TF; Hancox A; Hong JA; Chen GA; Pishchik V; Figg WD; Murgo AJ; Steinberg SM
Clin Cancer Res; 2006 Oct; 12(19):5777-85. PubMed ID: 17020984
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications.
Coral S; Sigalotti L; Colizzi F; Spessotto A; Nardi G; Cortini E; Pezzani L; Fratta E; Fonsatti E; Di Giacomo AM; Nicotra MR; Natali PG; Altomonte M; Maio M
J Cell Physiol; 2006 Apr; 207(1):58-66. PubMed ID: 16252259
[TBL] [Abstract][Full Text] [Related]
17. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine.
Weber J; Salgaller M; Samid D; Johnson B; Herlyn M; Lassam N; Treisman J; Rosenberg SA
Cancer Res; 1994 Apr; 54(7):1766-71. PubMed ID: 7511051
[TBL] [Abstract][Full Text] [Related]
18. Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine.
Yan M; Himoudi N; Basu BP; Wallace R; Poon E; Adams S; Hasan F; Xue SA; Wilson N; Dalgleish A; Williams O; Anderson J
Cancer Immunol Immunother; 2011 Sep; 60(9):1243-55. PubMed ID: 21553146
[TBL] [Abstract][Full Text] [Related]
19. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.
Pollack SM; Li Y; Blaisdell MJ; Farrar EA; Chou J; Hoch BL; Loggers ET; Rodler E; Eary JF; Conrad EU; Jones RL; Yee C
PLoS One; 2012; 7(2):e32165. PubMed ID: 22384167
[TBL] [Abstract][Full Text] [Related]
20. 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications.
Coral S; Sigalotti L; Altomonte M; Engelsberg A; Colizzi F; Cattarossi I; Maraskovsky E; Jager E; Seliger B; Maio M
Clin Cancer Res; 2002 Aug; 8(8):2690-5. PubMed ID: 12171902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]